4-[6-(pyridin-3-ylamino)pyridazin-3-yl]-N-[4-(trifluoromethylsulfanyl)phenyl]piperazine-1-carboxamide
C21H20F3N7OS — CID 122347587
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[6-(pyridin-3-ylamino)pyridazin-3-yl]-N-[4-(trifluoromethylsulfanyl)phenyl]piperazine-1-carboxamide
4-[6-(pyridin-3-ylamino)pyridazin-3-yl]-N-[4-(trifluoromethylsulfanyl)phenyl]piperazine-1-carboxamide (PubChem CID 122347587) has the molecular formula C21H20F3N7OS and a molecular weight of 475.50 g/mol. Its IUPAC name is 4-[6-(pyridin-3-ylamino)pyridazin-3-yl]-N-[4-(trifluoromethylsulfanyl)phenyl]piperazine-1-carboxamide.
Molecular Properties
| Compound Name | 4-[6-(pyridin-3-ylamino)pyridazin-3-yl]-N-[4-(trifluoromethylsulfanyl)phenyl]piperazine-1-carboxamide |
|---|---|
| PubChem CID | 122347587 |
| Molecular Formula | C21H20F3N7OS |
| Molecular Weight | 475.50 g/mol |
| Exact Mass | 475.14 |
| IUPAC Name | 4-[6-(pyridin-3-ylamino)pyridazin-3-yl]-N-[4-(trifluoromethylsulfanyl)phenyl]piperazine-1-carboxamide |
| SMILES | O=C(Nc1ccc(SC(F)(F)F)cc1)N1CCN(c2ccc(Nc3cccnc3)nn2)CC1 |
| InChI | InChI=1S/C21H20F3N7OS/c22-21(23,24)33-17-5-3-15(4-6-17)27-20(32)31-12-10-30(11-13-31)19-8-7-18(28-29-19)26-16-2-1-9-25-14-16/h1-9,14H,10-13H2,(H,26,28)(H,27,32) |
| InChIKey | MSACMVDODZVNCB-UHFFFAOYSA-N |
| XLogP | 4.58 |
| TPSA | 86.28 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 475.50 |
| LogP ≤ 5 | 4.58 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 122347587 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.